University residence hall network

ImmunOs Therapeutics Appoints Dr. Constanze Guenther as Senior Vice President, CMC and Technical Development

Retrieved on: 
星期二, 九月 19, 2023
Process, Change, University, Therapy, Senior, CMC, Cancer, Immuno AG, MBA, Research, University residence hall network, Doctor of Philosophy, HSG, Molecular Partners, Novartis, Biology, FDA, Technical, Inflammation, Pharmaceutical industry, Vaccine, Tisagenlecleucel, MD

In this role, she headed a team of technical project leads responsible for all CMC aspects of these programs.

Key Points: 
  • In this role, she headed a team of technical project leads responsible for all CMC aspects of these programs.
  • We are excited to have her join the team and lead our CMC and technical development efforts to develop and manufacture novel protein- and antibody-based therapies," said Steve Coats, PhD, Chief Development Officer at ImmunOs.
  • Her breadth and depth of expertise in technical development, manufacturing and operations will be important for advancing our first-in-class pipeline of multi-functional immunotherapies to and through clinical development."
  • "I believe that ImmunOs´ expertise in pioneering HLA-based therapeutics focusing on both oncology and immunology, led by IOS-1002, ImmunOs´ lead clinical candidate in oncology, is at the forefront of current research," said Dr. Constanze Guenther, Senior Vice President, CMC and Technical Development at ImmunOs.

PDA Announces Nearly 100 Exhibitors at the 19th Universe of Pre-Filled Syringes and Injection Devices Conference

Retrieved on: 
星期四, 九月 29, 2022
Universe, PDA, Drug delivery, Exhibition, Parenteral Drug Association, University residence hall network, Industry, Syringe, Patient, Organization, Technology, ANSI, Rise Up (conference), Science, UPS, Conference, Education, EMA, Pharmaceutical industry, EU

BETHESDA, Md., Sept. 29, 2022 /PRNewswire-PRWeb/ -- The Parenteral Drug Association, Inc. (PDA), today announced that 96 exhibitors will present their technologies at the first in-person Universe of Pre-Filled Syringes and Injection Devices (UPS) Conference since 2019. It will be held in Palm Springs, Ca., 18-19 Oct. The 2020 and 2021 conferences were held as virtual events.

Key Points: 
  • BETHESDA, Md., Sept. 29, 2022 /PRNewswire-PRWeb/ -- The Parenteral Drug Association, Inc. (PDA), today announced that 96 exhibitors will present their technologies at the first in-person Universe of Pre-Filled Syringes and Injection Devices (UPS) Conference since 2019.
  • "The organizing committee is delighted to welcome delegates back to the PDA Universe of Pre-Filled Syringes and Injection Devices Conference," said Mathias Romacker, committee co-chair and executive advisor, Kymanox.
  • "This year we are finally back to meet in person and so many new topics are there to be discussed.
  • Continued advances in materials of construction, manufacturing processes, injection processes and safety devices, and other technology improvements create a dynamic environment in the drug delivery device arena.

Moleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer

Retrieved on: 
星期三, 五月 4, 2022
University, Lymphoma, Risk, Gastroenterology, STS, Securities Exchange Act of 1934, SEC, University residence hall network, Antibody, Sint-Elisabeth Hospital, Clear-cell ovarian carcinoma, Twitter, MRCP, Company, Securities Act of 1933, Patient, FDA, Jazz Pharmaceuticals, Drug Quality and Security Act, Industry, Ovarian cancer, LinkedIn, Clinic, U.S. Securities and Exchange Commission, MET, Private Securities Litigation Reform Act, EMA, Neoplasm, Antimetabolite, Security (finance), Virus, Acute myeloid leukemia, NSCLC, MD, Leadership, MBA, Cancer, Brain, COVID-19, Department, Lung cancer, AML, T-cell lymphoma, Doctor of Philosophy, Therapy, Form 10-K, TKI, AstraZeneca, Terminology, Bristol Myers Squibb, Gefitinib, Pharmaceutical industry, Leukemia, Hematology, EU, Facebook

HOUSTON, May 4, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the Company has engaged Wolfram C. M. Dempke, MD, PhD, MBA, MRCP as its EU Chief Medical Officer and part-time contractor for its European clinical trials.  

Key Points: 
  • Dr. Dempke continues to teach classes in the Munich University Medical Oncology department, Germany, and he even continues to see patients on a monthly basis.
  • Walter Klemp, President and Chief Executive Officer of Moleculin commented, "As we look to commence our clinical studies in Europe, we believe Dr. Dempke will be a tremendous asset.
  • We are honored and pleased to have his leadership and guidance for our European clinical teams and help to drive these important programs forward."
  • Additionally he served as the Executive Medical Director and Global Clinical Lead (Global Medical Oncology) at AstraZeneca.